{"id":119565,"date":"2026-04-22T12:00:00","date_gmt":"2026-04-22T11:00:00","guid":{"rendered":"https:\/\/en.econostrum.info\/uk\/?p=119565"},"modified":"2026-04-22T10:47:56","modified_gmt":"2026-04-22T09:47:56","slug":"nationwide-recall-issued-for-blood-pressure","status":"publish","type":"post","link":"https:\/\/en.econostrum.info\/uk\/nationwide-recall-issued-for-blood-pressure\/","title":{"rendered":"Nationwide Recall Issued for Blood Pressure Medication Over Dose Confusion"},"content":{"rendered":"\n

A batch of a widely prescribed blood pressure medication has been recalled in the United Kingdom following a packaging error <\/strong>that may have led to incorrect dosing. Health authorities have issued guidance to both pharmacies and patients, emphasizing the need for verification rather than alarm.<\/p>\n\n\n\n

The recall concerns Ramipril<\/strong>, a medication commonly used to treat high blood pressure, heart failure, and kidney disease. While the issue has prompted swift action from regulators, officials stress that the risk to patients remains low, particularly over short-term use.<\/p>\n\n\n\n

Packaging Mix-up Prompts Nationwide Recall<\/strong><\/h2>\n\n\n\n

The Medicines and Healthcare products Regulatory Agency (MHRA<\/a>) announced the recall of one batch of Ramipril 10mg capsules manufactured by Crescent Pharma Limited<\/strong>. According to the MHRA, some cartons labeled as containing 10mg capsules may instead include blister strips of the lower 5mg dose.<\/p>\n\n\n\n

The issue was identified after a patient reported finding a mismatch inside a sealed package. According to the MHRA, one complaint revealed that a blister pack of Ramipril 5mg capsules had been placed inside a carton labeled for 10mg capsules<\/strong>. Investigators traced the problem to a manufacturing stage known as secondary packaging, where blister strips are inserted into cartons.<\/p>\n\n\n\n

Healthcare professionals have been instructed to immediately stop supplying the affected batch, identified as GR174091, and to return remaining stock to suppliers. Pharmacies <\/a>are also expected to contact patients who may have received the medication over the past year, with distribution dates ranging from May 2025 to April 2026, according to official guidance.<\/p>\n\n\n\n

The recall follows a similar incident reported the previous month involving Ramipril 5mg packs that mistakenly contained a different medication altogether. In both cases, the errors originated at the same manufacturing site, raising concerns about quality control during packaging processes.<\/p>\n\n\n\n

\n

Patient complaint forces blood pressure medication recallhttps:\/\/t.co\/3WWOSeDd7w<\/a>

The @MHRAgovuk<\/a> said the risk to patients is \u201cvery low\u201d and they should contact their pharmacy if they come across the packaging error in their Ramipril medication #pharmacy<\/a> #communitypharmacy<\/a>\u2026<\/p>— Chemist+Druggist (@ChemistDruggist) April 21, 2026<\/a><\/blockquote>